UA94580C2 - Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием - Google Patents

Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием

Info

Publication number
UA94580C2
UA94580C2 UAA200711241A UAA200711241A UA94580C2 UA 94580 C2 UA94580 C2 UA 94580C2 UA A200711241 A UAA200711241 A UA A200711241A UA A200711241 A UAA200711241 A UA A200711241A UA 94580 C2 UA94580 C2 UA 94580C2
Authority
UA
Ukraine
Prior art keywords
disease
treatment
medical condition
brain barrier
increased blood
Prior art date
Application number
UAA200711241A
Other languages
English (en)
Ukrainian (uk)
Inventor
Роза Мери Шеридан
Мингкьянг Жанг
Метью Алан Грегори
Original Assignee
Биотика Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биотика Текнолоджи Лимитед filed Critical Биотика Текнолоджи Лимитед
Publication of UA94580C2 publication Critical patent/UA94580C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
UAA200711241A 2005-03-11 2006-10-03 Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием UA94580C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0504995.2A GB0504995D0 (en) 2005-03-11 2005-03-11 Use of a compound

Publications (1)

Publication Number Publication Date
UA94580C2 true UA94580C2 (ru) 2011-05-25

Family

ID=34508874

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200711241A UA94580C2 (ru) 2005-03-11 2006-10-03 Аналог 39-дезметоксирапамицина, способный преодолевать гематоэнцефалический барьер, для лечения патологического состояния, вызванного нейрогенным повреждением или заболеванием

Country Status (5)

Country Link
US (2) US7183289B2 (ru)
CN (1) CN101180054A (ru)
GB (1) GB0504995D0 (ru)
RU (1) RU2428982C2 (ru)
UA (1) UA94580C2 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505932A (ja) * 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
KR101478164B1 (ko) 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
GB0618403D0 (en) * 2006-09-19 2006-11-01 Leuven K U Res & Dev Treatment of amyotrophic lateral sclerosis
WO2008124026A1 (en) * 2007-04-05 2008-10-16 Wyeth Wortmannin-rapamycin conjugate and uses thereof
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
WO2009023846A2 (en) * 2007-08-15 2009-02-19 The Research Foundation Of State University Of New York Methods for heat shock protein dependent cancer treatment
CA2716321A1 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
GB201122305D0 (en) * 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
US20210369684A1 (en) * 2018-02-09 2021-12-02 Torcept Therapeutics, Inc. Rapamycin analog for prevention and/or treatment of neurodegnerative conditions
JP2022515256A (ja) 2018-12-25 2022-02-17 ソル － ゲル テクノロジーズ リミテッド Ｅｇｆｒ阻害剤を含む組成物による皮膚障害の治療
CN111007161B (zh) * 2019-11-04 2021-03-26 中南大学 一种预测甲氨蝶呤药效的肽段组合物及其定量检测方法与检测试剂盒
WO2022179575A1 (zh) * 2021-02-25 2022-09-01 中以海德人工智能药物研发股份有限公司 雷帕霉素在治疗或预防乙型肝炎中的应用
WO2025147266A1 (en) * 2024-01-06 2025-07-10 Jose Vega Method of mitigation of death from epileptic seizures

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
JP3140228B2 (ja) 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
GB9315914D0 (en) * 1993-07-31 1993-09-15 Smithkline Beecham Plc Novel compound
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6485514B1 (en) * 1997-12-12 2002-11-26 Supergen, Inc. Local delivery of therapeutic agents
CN1551767A (zh) * 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
WO2005003335A2 (en) * 2003-06-12 2005-01-13 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rapamycin resistant t cells and therapeutic uses thereof
EP1478648B1 (en) * 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
ES2544624T3 (es) 2002-07-16 2015-09-02 Buck Institute For Research On Aging Producción de policétidos
KR20070116868A (ko) * 2005-03-11 2007-12-11 바이오티카 테크놀로지 리미티드 ３９­데스메톡시라파마이신 및 그 유사체의 의학적 용도

Also Published As

Publication number Publication date
US7655673B2 (en) 2010-02-02
US20070184075A1 (en) 2007-08-09
RU2428982C2 (ru) 2011-09-20
US7183289B2 (en) 2007-02-27
CN101180054A (zh) 2008-05-14
US20060205757A1 (en) 2006-09-14
GB0504995D0 (en) 2005-04-20
RU2007137669A (ru) 2009-04-20

Similar Documents

Publication Publication Date Title
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
SG145693A1 (en) Amino acid prodrugs
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
LT2878297T (lt) Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai
MX374396B (es) Rocio de fentanilo sublingual.
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
PT1855677E (pt) 3-11b-cis-di-hidrotetrabenazina para o tratamento da esquizofrenia e de outras psicoses
MX2008010035A (es) Compuestos de n-hidroxiacrilamida.
WO2008129422A8 (en) Demannosylated recombinant factor viii for the treatment of patients with haemophilia a
NO20076405L (no) Anvendelse av 24-nor-UDCA
UA97401C2 (ru) Экструдат с улучшенной маскировкой вкуса
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
MX2007012538A (es) Uso de lactobacillus gg en la manufactura de un medicamento para la prevencion o tratamiento de alergias respiratorias.
WO2009043858A3 (en) Methods for treating and diagnosing a cancer secreting cath-d or alzheimer's disease
MXPA06013039A (es) El tratamiento de enfermedad respiratoria.
TW200700071A (en) Novel use
UA96926C2 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
EP2446887A3 (en) Use of danazol for the treatment of Alzheimer's disease
ZA200707486B (en) Use of 2-(2-nitro-4-trifluoromenthylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease
TW200640467A (en) Compounds and uses thereof
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
UA92586C2 (ru) Лечение или предотвращение респираторных вирусных инфекций с помощью иммуномодуляторов
PL1612210T3 (pl) Nowe analogi nitrobenzylotioinozyny
WO2008034202A3 (en) Use of ivermectin and derivates thereof for the treatment of amyotrophic lateral sclerosis